CytomX Therapeutics, Inc.
CTMX
$3.79
-$0.09-2.32%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -44.82% | -10.26% | 18.01% | 23.81% | 36.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -44.82% | -10.26% | 18.01% | 23.81% | 36.45% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -44.82% | -10.26% | 18.01% | 23.81% | 36.45% |
| SG&A Expenses | -3.33% | -11.99% | -3.77% | 5.39% | -0.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.33% | -24.62% | -13.94% | 3.00% | 5.02% |
| Operating Income | -178.28% | 246.44% | 653.67% | 232.15% | 485.49% |
| Income Before Tax | -153.38% | 87.67% | 219.88% | 104.35% | 865.75% |
| Income Tax Expenses | 6.28% | -80.08% | -93.79% | -94.01% | -94.27% |
| Earnings from Continuing Operations | -154.50% | 102.59% | 332.83% | 151.64% | 5,700.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -154.50% | 102.59% | 332.83% | 151.64% | 5,700.88% |
| EBIT | -178.28% | 246.44% | 653.67% | 232.15% | 485.49% |
| EBITDA | -167.96% | 186.81% | 486.76% | 192.43% | 721.10% |
| EPS Basic | -97.70% | 138.57% | 301.66% | 141.21% | 2,103.17% |
| Normalized Basic EPS | -88.25% | 120.28% | 197.87% | 95.16% | 1,209.34% |
| EPS Diluted | -99.01% | 143.38% | 316.39% | 146.64% | 1,633.06% |
| Normalized Diluted EPS | -88.21% | 121.82% | 199.83% | 96.10% | 1,212.15% |
| Average Basic Shares Outstanding | 63.11% | 39.99% | 17.57% | 10.29% | 14.46% |
| Average Diluted Shares Outstanding | 62.77% | 39.70% | 17.30% | 10.03% | 14.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |